Clinical trials: Schizophrenic Disorder
Psychotic Disorders
Epidemiology Study of Psychosis
Purpose Psychotic disorders (including schizophrenia) are complex neurobehaviour disorders influenced by genetic, neurodevelopmental, neurochemical, as well as psychosocial factors.
- Trial name
- NCT01423669
- Where
- China
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Schizophrenia, Mania
Aripiprazole Pharmacokinetics (PK) and Tolerability Study in Children and Adolescents
The purpose of this trial is to assess the safety, tolerability and pharmacokinetics of aripiprazole tablets following oral administration to children and adolescents.
- Trial name
- NCT00102479
- Testing
- Aripiprazole
- Volunteers
- 21 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Mental Health Issue (E.G., Depression, Psychosis, Personality Disorder, Substance Abuse)
Brain Imaging in Early Psychosis
This study assesses brain connectivity and function of individuals ages 13-25 at a prodromal or early stage of a psychotic disorder.
- Trial name
- NCT03932188
- Testing
- Mental Health Assessments and Computerized Cognitive Test, MRI scan
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Schizophrenia
A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia
The objective of this study is to investigate the safety and efficacy of aripiprazole (initial dose 2 mg/day, maintenance dose 6-24 mg/day, maximum dose 30 mg/day) orally administered over a period of 52 weeks in subjects who…
- Trial name
- NCT01942148
- Testing
- Aripiprazole
- Where
- 8 sites in Japan
- Volunteers
- 68 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Major Depressive Disorder (MDD), SCHIZOPHRENIA 1 (Disorder)
Transcranial Direct Current Stimulation (tDCS) in Different Psychiatric Disorders
The goal of this clinical trial is to evaluate the efficacy and safety of transcranial direct current stimulation (tDCS) in reducing core symptoms of different psychiatric disorders using validated clinical scales.
- Conditions
- Major Depressive Disorder (MDD), SCHIZOPHRENIA 1 (Disorder), Obsessive-Compulsive Disorder, Generalized Anxiety Disorder
- Trial name
- Transcranial (NCT07452835)
- Testing
- tDCS Parameters
- Where
- Egypt
- Volunteers
- 320 people
- Sponsor
- Menoufia University
Early Psychosis
Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis
This is an outpatient, single center, between-group, double blind, placebo controlled design. Approximately 120 adolescents and adult patients will be randomized to either have their treatment augmented with Cannabidiol Oral…
- Trial name
- NCT04411225
- Testing
- Cannabidiol oral solution
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- University of California, San Diego
Schizophrenia
Perception of Facial Emotions in Schizophrenia and 22q11 Deletion Syndrome
Background: The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in schizophrenia and the 22q11.2 deletion syndrome, and thus, reveal a distinction between the two…
- Trial name
- FaSchi22 (NCT02634671)
- Testing
- schizophrenia, the 22q11 deletion syndrome, control group
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Hôpital le Vinatier
Schizophrenia
PREvent First Episode Relapse (PREFER)
Many patients who have recently received a diagnosis of schizophrenia (e.g., "first-episode schizophrenia") respond very well to their antipsychotic medication when they are acutely ill.
- Trial name
- NCT00220714
- Testing
- atypical antipsychotics:oral vs. long-acting route, Family Psychoeducation
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- State University of New York - Downstate Medical Center
Schizophrenia and Disorders With Psychotic Features, Affective Psychosis, Bipolar
Duration of Untreated Psychosis (DUP) and Pathways to Care in Nordland
During the 1990s, evidence began to emerge of the long duration of untreated illness prior to receiving treatment for patients with psychotic disorders.
- Conditions
- Schizophrenia and Disorders With Psychotic Features, Affective Psychosis, Bipolar, Psychoses
- Trial name
- NCT01196858
- Where
- Norway
- Volunteers
- 62 people
- Sponsor
- University Hospital of North Norway
Psychotic Disorders, Anxiety
A Study of Dose-response Relationship and the Evidence Based Multisensory Stimulation Intervention
Design: This parallel randomized controlled trial (RCT) was conducted according to the Consolidated Standards of Reporting Trials (CONSORT).
- Conditions
- Psychotic Disorders, Anxiety, Complementary Therapies, Clinical Trial
- Trial name
- NCT05012709
- Testing
- multisensory stimulation therapy
- Where
- Taiwan
- Volunteers
- 95 people
- Sponsor
- Jianan Psychiatric Center, Ministry of Health and Welfare
Schizophrenia
Effects of Exposed to Antipsychotics Throughout Pregnancy on Infants Development: A Prospective Study
The primary aim of this prospective study is to evaluate the effect of antipsychotics on infant development especially neurobehavioral development which evaluated by the Bayley-III when mothers are treated with antipsychotics…
- Trial name
- NCT01479400
- Where
- China
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Central South University
Clinical High Risk for Psychosis (CHR), Suicidal Ideation
Developing a Recovery-Oriented Suicide Prevention Program for Young People at Clinical High Risk for Psychosis
Young people at clinical high risk for psychosis are more likely to experience suicide thoughts than the general population, but there are few suicide prevention programs designed specifically for them.
- Conditions
- Clinical High Risk for Psychosis (CHR), Suicidal Ideation, Psychosis, Suicidal Behavior
- Trial name
- NCT07756567
- Testing
- Suicide Prevention Intervention, Standard Care (in control arm)
- Where
- 2 sites in United States
- Volunteers
- 108 people
- Sponsor
- University of California, San Diego
Schizophrenia Prodrome
Ethyl-EPA Treatment of Prodromal Patients
This is an open-label trial of an omega-3 fatty acid for symptoms of the schizophrenia prodrome.
- Trial name
- NCT00634361
- Testing
- ethyl-eicosapentaenoic acid
- Volunteers
- 7 people
- Sponsor
- Yale University
Hyperprolactinemia, Weight Gain
Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia
This is a prospective, open-label study to evaluate the efficacy and safety in reducing antipsychotic-induced hyperprolactinemia, weight gain, and dyslipidemia by aripiprazole.
- Conditions
- Hyperprolactinemia, Weight Gain, Dyslipidemia
- Trial name
- NCT00541554
- Testing
- Abilify (aripiprazole)
- Sponsor
- Genovate Biotechnology Co., Ltd.,
Dissociative Disorders, Schizophrenia
Assessment of Adverse Events in a Naive Pediatric Population Treated With an Antipsychotic
We propose a prospective multicenter study, whose originality lies in the inclusion of the naive child and adolescent population.
- Trial name
- NCT02007928
- Testing
- Rispéridone, aripiprazole, olanzapine
- Where
- 14 sites in France
- Volunteers
- 200 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Schizophrenia, Psychotic Disorders
Enhancing the Prospective Prediction of Psychosis
This study will gather information on the natural history of the basic symptoms of psychosis to identify factors that may affect the improvement or persistence of the symptoms.
- Trial name
- NCT00291200
- Where
- 3 sites in United States, Canada
- Volunteers
- 268 people
- Sponsor
- Yale University
Schizophrenia
Oral Aripiprazole Open-Label Rollover Study
The purpose of this study is to test the long-term safety and tolerability of oral aripiprazole in adolescent patients with schizophrenia.
- Trial name
- NCT01001702
- Testing
- Aripiprazole
- Where
- 15 sites in Argentina, Croatia and 4 more
- Volunteers
- 85 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Parkinson's Disease Psychosis, Dementia With Lewy Bodies
Comparing Antipsychotic Medications in LBD Over Time
The primary objective of this study is to determine whether treatment with pimavanserin or quetiapine is associated with a greater improvement in psychosis when used in a routine clinical setting to treat hallucinations and/or…
- Trial name
- CAMELOT (NCT05590637)
- Testing
- Pimavanserin, Quetiapine
- Where
- 2 sites in United States
- Volunteers
- 94 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Psychosis
Virtual Reality and Artificial Intelligence in Treatment for Patients With Psychosis
Virtual Reality (VR) has gained momentum in the treatment of various mental health conditions. Despite its potential and emphasis on better use of technology in healthcare strategies, VR therapy for severe mental illness remains…
- Trial name
- RecoVRy (NCT06728241)
- Testing
- RecoVRy, VR Games
- Where
- 2 sites in Norway
- Volunteers
- 150 people
- Sponsor
- Oslo University Hospital
Psychotic Disorders, Cannabis Use Disorder
Investigating the Neural Correlates of Cognitive Function in Psychosis Patients and Non-Psychiatric Controls With Cannabis Use
Cognitive impairment is well established in people with psychosis and is associated with cannabis use. The current study will investigate the neurobiological basis of cognitive change associated with 28-days of cannabis…
- Conditions
- Psychotic Disorders, Cannabis Use Disorder, Cannabis Dependence, Cannabis Use
- Trial name
- NCT05445180
- Testing
- Contingency management
- Where
- Canada
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Douglas Mental Health University Institute